Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 crore

Promoter Fosun Pharma on Friday sold 98.97 lakh shares, equivalent to around 6% equity, in Gland Pharma for an estimated Rs 2,800 crore through a block deal, according to the exchange data.

Fosun Pharma held 8,53,93,894 shares, or 51.77% stake, in the pharmaceutical company as of the quarter ended June 30, 2026, as per BSE data. Following the stake sale, its holding would come down to around 45.77%.

Kotak Mahindra Mutual Fund, Axis Mutual Fund and ICICI Prudential Mutual Fund were among the buyers.


Kotak Mahindra MF bought 27.93 lakh shares, or 1.69% stake, for Rs 789 crore, while Axis MF acquired 13.57 lakh shares, equivalent to 0.82% stake, for Rs 384 crore. ICICI Prudential Mutual Fund purchased 10.39 lakh shares, or 0.63% stake, for Rs 294 crore.

The three mutual funds bought the shares at an average price of Rs 2,826.6 per share.

Meanwhile, Gland Pharma shares ended Friday’s trading session at Rs 2,932.40 apiece, up 0.84% from the previous close of Rs 2,907.90. The stock had fallen to a low of Rs 2,827 during the session following the block deal.

ALSO READ: Mega NSE IPO coming as Sebi approves Rs 30,000 crore public offer

Earlier on September 1, Gland Pharma informed the exchanges that the United States Food and Drug Administration (USFDA) had conducted a routine Good Manufacturing Practice (GMP) inspection at the company’s VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam between August 24 and September 1. The inspection concluded with zero Form 483 observations.

On August 10, Gland Pharma reported a consolidated net profit of Rs 317 crore for Q1FY27, up 47% year-on-year from Rs 216 crore in the corresponding quarter last year. Revenue from operations rose 20% year-on-year to Rs 1,800 crore from Rs 1,506 crore in Q1FY26.

During Q1FY27, the company’s quarterly R&D investment stood at Rs 77.2 crore, while adjusted EBITDA increased 37% year-on-year. The adjusted EBITDA margin stood at 28%. The CDMO business contributed 50% of total revenue and recorded 20% year-on-year growth during the quarter. The B2B business accounted for the remaining 50% of revenue and grew 19% year-on-year.

Established in Hyderabad in 1978, Gland Pharma has grown from a contract manufacturer of small-volume liquid parenteral products to a generic injectable manufacturing company with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.

The company primarily operates under a business-to-business (B2B) model and has a track record in pharmaceutical research and development, manufacturing and marketing of complex injectables.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)